Showing results (1-10 of 12) with videos related to
Sort By:
Pageof 2
Journal of Drugs in Dermatology : JDD|December 3, 2011
Safety and efficacy of clindamycin phosphate 1.2%-benzoyl peroxide 3% fixed-dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double-blind, active- and vehicle-controlled studyLawrence F Eichenfield, Alessandra B Alió SáenzCutis|December 29, 2012
Phototoxic and photoallergic potential of tazarotene foam 0.1% in 2 phase 1 patch studiesDaniel J Hogan, Alessandra B Alió SaenzCutis|February 3, 2011
Randomized tolerability analysis of clindamycin phosphate 1.2%-tretinoin 0.025% gel used with benzoyl peroxide wash 4% for acne vulgarisZoe Diana Draelos, Aaron Potts, Alessandra B Alió Saenz, et al.Clinical Pharmacology in Drug Development|April 29, 2016
Bioavailability of Clindamycin From a New Clindamycin Phosphate 1.2%-Benzoyl Peroxide 3% Combination GelTerry M Jones, Stacy Jasper, Alessandra B Alió SáenzClinical Drug Investigation|March 5, 2013
Tazarotene foam versus tazarotene gel: a randomized relative bioavailability study in acne vulgarisMichael Jarratt, Cary P Werner, Alessandra B Alió SaenzJournal of Drugs in Dermatology : JDD|May 9, 2013
The efficacy and tolerability of tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studiesSteven R Feldman, Cary P Werner, Alessandra B Alió SaenzCutis|December 25, 2012
Cumulative irritation potential and contact sensitization potential of tazarotene foam 0.1% in 2 phase 1 patch studiesJeffrey E Berg, James P Bowman, Alessandra B Alió SaenzCutis|August 15, 2006
Sjögren-Larsson syndrome: a case report and literature reviewAlessandra B Alió, Lynne M Bird, Scott D McClellan, et al.Pediatric Dermatology|April 28, 2007
Epstein-Barr virus-associated genital ulcers: an under-recognized disorderCheryl J Barnes, Alessandra B Alió, Bari B Cunningham, et al.Journal of Drugs in Dermatology : JDD|February 5, 2013
Long-term safety of ketoconazole foam, 2% in the treatment of seborrheic dermatitis: results of a phase IV, open-label studyZoë D Draelos, Steven R Feldman, Victoria Butners, et al.Pageof 2